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Abstract
The second scientific workshop of the European Crohn's and Colitis Organization (ECCO) focused
on the relevance of intestinal healing for the disease course of inflammatory bowel disease
(IBD). The objective was to better understand basic mechanisms, markers for disease prediction,
detection and monitoring of intestinal healing, impact of intestinal healing on the disease course
of IBD as well as therapeutic strategies. The results of this workshop are presented in four sep-
arate manuscripts. This section describes basic mechanisms of intestinal healing, identifies open
questions in the field and provides a framework for future studies.
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
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The Scientific Committee of the European Crohn's and Colitis
Organization (ECCO) has launched a scientific workshop inAbbreviations 5-ASA, 5-aminosalicylic acid; AZA, Azathioprine; bFGF
kine (CXC motif) receptor; DAMP, Damage associated molecular pattern
EMT, Epithelial mesenchymal transformation; FAK, Focal adhesion kinas
inducible factors; IBD, Inflammatory bowel disease; ICAM, Intercellular a
growth factor; IL, Interleukin; IP, Interferon gamma-induced protein; LF
vated protein kinase; MIF, Macrophage migration inhibiting factor; MMP,
light-chain-enhancer of activated B cells; NOD, Nucleotide-binding oligo
sociated molecular pattern molecules; PI3K, Phosphoinositide-3 kinase;
actin; SNP, Single nucleotide polymorphism; SOD, Superoxide dismutase
factors; TGF, Transforming growth factor; TIMP, Tissue inhibitor of matri
sulfonic acid; TNF, Tumor necrosis factor; UC, Ulcerative colitis; VCAM,
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course of inflammatory bowel disease (IBD). The overall ob-
jective of this workshop was to better understand and explore
the importance of intestinal healing in IBD. The outcome of, Basic fibroblast growth factor; CD, Crohn's disease; CXCR, Chemo-
molecules; DSS, Dextrane sodium sulfate; ECM, Extracellular matrix;
e; FOX, Forkhead box; FSP, Fibroblast specific protein; HIF, Hypoxia
dhesion molecule 1; IFN, Interferon; IFX, Infliximab; IGF, Insulin-like
A-1, Lymphocyte function-associated antigen 1; MAPK, Mitogen acti-
Matrix metalloproteinase; MUC, Mucin; NFκB, Nuclear factor kappa-
merization domain containing; NO, Nitric oxide; PAMP, Pathogen as-
SLPI, Secretory leucocyte protease inhibitor; SMA, Smooth muscle
; TAK, Transforming growth factor-β activated kinase; TFF, Trefoil
x metalloproteinase; TLR, Toll like receptor; TNBS, Trinitro-benzene
Vascular cell adhesion molecule 1
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mechanisms of intestinal healing (basic science), measures
and markers to detect, achieve, and monitor intestinal heal-
ing, impact of intestinal healing on the course of IBD (natural
history), and therapeutic strategies to enhance intestinal heal-
ing (therapy). This manuscript summarizes current knowledge
about basic mechanisms of intestinal healing and discusses
several key issues that need to be addressed in future studies.
The achievement of mucosal healing is a critical endpoint
in the treatment of patients with both ulcerative colitis (UC)
and Crohn's disease (CD). Achievement of mucosal healing in
patients with IBD carries the prospect of influencing the nat-
ural history of this disease by the prevention of complica-
tions, such as need for surgery or hospitalization rates. The
understanding of basic mechanisms of wound generation
and healing is crucial for the improvement of existing and
development of future therapies. It is not only important
to evaluate key mechanisms in mucosal injury but also to dis-
cuss early as well as late events in the intestinal wound heal-
ing response. Striking differences in wound healing between
different IBD patients can be observed, which could be
explained by differences in genetic or epigenetic factors,
differences in the intestinal luminal components or distinct
responses to drug therapies.2. Definition of and players in intestinal wound
generation in IBD
2.1. Definition of mucosal injury
The commonly used definition of mucosal injury generally
refers to macroscopically visible mucosal lesions during en-
doscopy, and this definition will be used hereafter. Howev-
er, this term, which is helpful for clinical purposes, should
be distinguished from the immune-mechanistic concept
of mucosal injury, as employed in the research arena. This
immune-mechanistic definition is multi-layered and encom-
passes several strata: gap junction disruption at a molecular
level, increased epithelial permeability at a sub-cellular
level, epithelial apoptosis, infiltration of activated inflam-
matory and lymphocytic cells at the cellular level, villous
and crypt architectural changes, granuloma formation and
disruption of the muscularis layer at the microscopic tissue
level, and finally — the creation of erosions and ulcers mac-
roscopically visible by endoscopic examination.
Moreover, in the current terminology, it is not universal-
ly agreed upon whether an isolated inflammatory process
(for instance lamina propria inflammatory cell infiltration)
qualifies for a mucosal injury or should this term be reserved
for epithelial disruption only. Furthermore, it remains to be
defined if mucosal healing should denote only a process re-
stricted to the mucosa or should it include also the healing
of sub-mucosa and muscularis layers as well as neuronal
and lymphangiogenic elements of the intestinal wall.2.2. Key players in mucosal injury
Mucosal injury is likely initiated by a combination of endoge-
nous and environmental factors. At first stage, it is believed
that food-derived compounds, viral and bacterial-derivedfactors as well as host-derived factors may cause epithelial
cell destruction leading to pathogen-associated molecular
pattern molecule (PAMP) and damage associated molecular
pattern molecule (DAMP)-dependent activation of innate and
adaptive immunity. Damaged mucosa is initially infiltrated by
diverse inflammatory cells consisting of neutrophils, eosino-
phils, mast cells, inflammatory monocytes, activated macro-
phages and dendritic cells. In parallel, specific adaptive
immune responses toward the intestinal flora are generated
leading to the later recruitment of activated B cells, CD4+
and CD8+ T cells to the inflamed mucosa.
A number of molecules have been implicated in mediating
the epithelial damage in IBD, leading to discernable mucosal le-
sions, but often their actual function and mechanism of action
remain unclear. Thesemolecules include, but are not restricted
to:
2.2.1. Tumor necrosis factor-α (TNF)
TNFwas shown to induce intestinal epithelial cell apoptosis,1,2
an effect that is abrogated by the ErbB4 growth factor recep-
tor.3 However, it was also demonstrated that TNF exerts anti-
apoptotic effects mediated by ErbB2 and epidermal growth
factor (EGF) receptor,4 and that increased TNF levels corre-
late with inactive disease and lack of mucosal injury.5 There-
fore, the exact role of TNF in instigating mucosal damage
remains to be determined.
2.2.2. Reactive oxygen and nitrogen species
Thesemostly include superoxide O2− and nitric oxide NO−which
have been implicated in induction and propagation of epitheli-
al mucosal injury.6 Increased levels of inducible nitric oxide
(NO) synthase (iNOS) were found in IBD. iNOS knock-out mice
were protected against dextrane sodium sulfate (DSS) colitis7
and experienced ameliorated trinitro-benzene sulfonic acid
(TNBS) colitis when housed under SPF conditions.8 Notwith-
standing, these iNOS knock-out animals paradoxically suffered
from exaggerated colitis when induced by TNBS in non-specific
pathogen free conditions9 or when colitis was induced by the
acetic acid model.10
Superoxide O2− has been similarly implicated in the etiogen-
esis ofmucosal damage in IBD. High levels of the enzyme super-
oxide dismutase (SOD) that catalyses and eliminates O2−was
documented in IBD mucosa.11 Lactobacillus expression of SOD
ameliorated intestinal inflammation in interleukin (IL)-10 defi-
cient mice12 and in a rat TNBS colitis model.13 In contrast, SOD
overexpressingmice, expected to have highermetabolic clear-
ance of O2−, paradoxically exhibited more severe DSS-induced
colitis compared to wild type mice.7 It remains unclear, if a
certain threshold level of mucosal O2− is required for efficient
clearance of invading bacteria.
2.2.3. Matrix metalloproteinases (MMP)
Alterations in extracellular matrix (ECM) remodeling
brought upon by an imbalance of certain MMPs and/or
their inhibitors (in particular TIMP-1) have been implicated
in inducing intestinal lesions in IBD. MMP-2, MMP-14, and
TIMP-1 were increased significantly in the ulcerated mucosa
of IBD patients but only slightly elevated in inflamed non-
ulcerated section of intestine.14 Moreover, MMP-1,2,3 and
9were increased in inflamedmucosa of IBD patients compared
to the unaffected mucosa.14,15 Inhibition of MMP activity was
shown to ameliorate TNBS colitis.16 One possible mechanism
376 F. Rieder et al.for the preservation ofmucosal integrity is action through sub-
stance P induced colonocyte proliferation.17
2.2.4. Leptin
Leptin was found to induce intestinal epithelial damage via
activation of nuclear factor kappa-light-chain-enhancer of
activated B cells (NFκB).18 In contrast, NFκB activation
(not by leptin) was essential for protection of intestinal epi-
thelial cells from ischemia-induced apoptosis2,19 and
probiotic-induced protection from colitis.20
2.2.5. Hypoxia inducible factor (HIF)
HIF was found protective against TNBS colitis by enhancing
barrier function and epithelial integrity,21,22 but pro-
inflammatory in DSS colitis by a macrophage migration inhib-
itory factor (MIF) dependent mechanism.23 These contradic-
tory results were attributed to differences in the models
used, namely the robust T-cell response in TNBS colitis as op-
posed to DSS, as well as to distinct effects of different HIF
family members.
While multiple molecules and complex mechanisms seem
to be instrumental in initiation and propagation of mucosal
injury, a fundamental question remains unresolved: Why do
certain areas of the gut exhibit mucosal injury while others
remain unaffected? In ulcerative colitis patients high levels
of pro-inflammatory cytokines, such as interferon (IFN)-γ,
TNF, IL-6, IL-15, IL-18, and IL-23, can be found in endoscop-
ically affected and unaffected mucosa. Interestingly, media-
tors of direct mucosal injury (MMP-3, TIMP-1, iNOS,
Granzyme-B) were elevated only in the affected mucosa.24
In CD patients only Granzyme B was elevated in affected
but not unaffected mucosa, whereas TIMP-1 and iNOS were
upregulated independently of endoscopic involvement.24 In
addition, cathepsins have been shown to contribute to mu-
cosal damage.25,26 Thus, the differentiation between visibly
ulcerated mucosa and normal appearing yet inflamed muco-
sa may be partly accounted for by the progression of the in-
flammatory process with up-regulation and/or expression of
tissue damage mediators. It seems clear, however, that
there are other yet undefined mechanisms at play in dictat-
ing the progression to visible mucosal damage.
2.3. Key messages and questions to address in the
future
Key messages• The endoscopic definition of mucosal injury needs to be
separated from the immune mechanistic definition.
• Mucosal injury is initiated by a multitude of endogenous
and environmental factors and involves molecules, such
as tumor necrosis factor, reactive oxygen species, matrix
metalloproteinases, leptin, cathepsins and hypoxia induc-
ible factor
Questions to address in the future
• We need to determine, which definition of mucosal injury
or healing correlates best with the subsequent clinical
course. Is it only the endoscopically visible lesion orwould microscopic or even molecular perturbance of muco-
sal elements prove to be better predictors?
• What are the specific food-derived compounds, virus and
bacteria-derived factors and host-derived or environmental
danger signals inducing and perpetuating epithelial cell
destruction?
• What is the specific mode of action of the above named
mediators in pathogenesis of mucosal injury and healing?
• What triggers the progression from inflamed yet visually
preserved mucosa to an inflamed overtly ulcerated mucosa
and vice versa.3. Early events in healing
3.1. Definition of early intestinal healing
The gastrointestinal mucosa provides a critical barrier, sep-
arating a myriad of environmental antigens within the intes-
tinal lumen from the immune system of the host organism.27
Thus, early gastrointestinal wounding can be defined as a
breakdown of the mucosal barrier function, leading to the
translocation of antigens to the mucosal lamina propria,
which is followed by the induction of acute and chronic in-
flammatory responses. Consequently, early mucosal wound
healing can be described as the reestablishment of the intes-
tinal mucosal barrier function.
Within the complex context of early gastrointestinal
wounding and wound healing, several mechanistic compo-
nents can be separated. Rather than providing a comprehen-
sive review that has been given elsewhere28–30 we will
concentrate our presentation on the contribution of the lu-
minal mucus compartment, endogenous antimicrobial pep-
tides, and the intestinal epithelial cell layer to the early
events in intestinal wound healing.3.2. Gastrointestinal mucus layer
For a long time it has been known that goblet cell depletion
is a common phenomenon in IBD. Recent methodological ad-
vances allowed for the definition of sophisticated substruc-
tures within the gastrointestinal mucus layer (e.g. its
phosphatidylcholine layer, lamellar bodies, mucin composi-
tion and glycosylation),28,31 which have been demonstrated
to be of crucial importance for its barrier function.32–34
The mucous layer and the bacteria residing in this compart-
ment form a protective ‘living wallpaper’ against exogenous
bacteria through colonization resistance. Once the gastroin-
testinal mucus layer is disrupted, bacteria can penetrate the
mucus and get in direct contact with epithelial cells, endan-
gering mucosal homeostasis.35,36 It is however likely that not
only early mucosal wounding but also wound healing starts at
the level of the intestinal mucus layer. An intact mucus layer
is critical to immediately fill the gaps in an injured epithelial
layer, providing an initial ‘seal’ and thus preventing further
damage.37,38 Understanding the mechanisms of how mucus
is secreted, composed and modified and how these process-
es are altered in IBD, are therefore highly important for de-
velopment of further therapeutic approaches.39
377Second ECCO Scientific Workshop – Basic mechanisms3.3. Paneth cells and defensins
After disruption of the intestinal mucus and direct contact of
the intestinal microbiota with the epithelial cell monolayer a
second line of defense against bacterial invaders is of increasing
importance: Paneth-cell- as well as enterocyte-derived defen-
sins. Once secreted they become part of the intestinal mucus
and their antimicrobial activity is crucial for themucosal barrier
function.40–42 Its disruption has been associated with the devel-
opment of intestinal inflammation in mouse models as well as
chronic IBD in humans.43–45 It is therefore likely that insufficient
anti-bacterial activity in proximity to the epithelial cell mono-
layer leads to an impaired earlywound healing response, and fu-
ture efforts should target an early reestablishment of this
compartment.3.4. Intestinal epithelial repair
Intestinal mucosal lesions in IBD, encompassing numerous cells
within the intestinal epithelial cell monolayer, necessitate a
rapid resealing mechanism initiated by cells adjacent to the
wound edges, which dedifferentiate (epithelial–mesenchymal
transition, EMT), migrate over the wound to close the gap and
re-differentiate including the formation of tight junctions.46
Smaller lesions allow a local purse-string mechanism via myo-
sin light chain kinase activation in the epithelial cells surround-
ing the defect, rapidly closing the gap.47,48 Host-derived
factors support these healing mechanisms, e.g. growth factors
and cytokines.49–52 Additionally, luminal factors (both host-
derived and generated in the luminal environment) support in-
testinal epithelial wound healing, including intestinal trefoil
factors (TFF, highly protease-resistant peptides secreted by
goblet cells or their equivalents), bile acids, short chain fatty
acids, adenine nucleotides, trace elements and the intestinal
luminal microbiota themselves.52–57
On the molecular level, these mediators induce multiple
signaling events within intestinal epithelial cells, including
NFκB-, mitogen activated protein kinase (MAPK)p38-, trans-
forming growth factor (TGF)-β activated kinase (TAK)1-, focal
adhesion kinase (FAK)-activation via Smad2/3 and protein
kinase Akt-activation via phosphoinositide-3 kinase (PI3K) and
via ErbB4. Downstream these signaling events exert mostly
anti-apoptotic, pro-proliferative as well as pro-migratory
effects.3,58–62 Remarkably, many of these signaling mecha-
nisms can also be induced independently of external factors
through simple mechanical wounding of an intestinal epithelial
cell monolayer alone.63–66 However, the exact mechanisms
leading to the activation of the various signaling pathways via
mechanical wounding in enterocytes remain to be elucidated.
Of note, many of the signaling molecules activated during
intestinal epithelial wound-healing play an important role dur-
ing acute and chronic intestinal inflammation as well.67–70 As
intestinal epithelial wound infliction and healing are almost in-
variably occurring in an inflammatory context, pro- and anti-
inflammatory signaling pathways and molecular events during
wound healing form a complex and mutually interactive net-
work. Importantly, treatment regimens aimed at suppressing
certain pro-inflammatory signaling have proven to be deleteri-
ous via suppression of wound healing responses, especially in
the presence of intestinal damage.19,71 Further dissecting the
intricate signaling network modulating intestinal epithelialcell proliferation, migration and apoptosis in gastrointestinal
homeostasis and disease will be a prerequisite for the develop-
ment of new therapeutic means aimed at these processes.
Technically, it has proven challenging to imitate local intes-
tinal epithelial wounding and wound healing in a controlled
model system in vivo. Puncture wounds created by endoscopic
techniques have been used,72 as has beenmucosal ulcer gener-
ation via acetic acid saturated filter discs applied to the serosal
side of the small bowel.60,73 Recently, two-photon laser tech-
nology allowed the generation of wounds encompassing single
intestinal epithelial cells.38 On the other hand, loss of epitheli-
al cells is not a prerequisite of breaches of the intestinal epi-
thelial barrier: Since the intestinal epithelial cell monolayer
has to be selectively permeable to allow for nutrient, electro-
lyte and water absorption, its ‘sealing mechanism’ (namely
tight junctions located apically between the enterocytes) is
constantly replenished and modified. Thus, apart from macro-
scopically distinguishable breaches like for example the loss of
epithelial cells, ‘molecular breaches’ in tight junction perme-
ability could be important in early wound generation (compre-
hensive review given in30,74).
3.5. Key messages and questions to address in the
future
Key messages
• Early intestinal healing can be defined as the re-
establishment of the mucosal barrier function.
• The gastrointestinal mucus layer is of critical importance for
the repair and maintenance of the intestinal barrier function.
• Disruption of endogenous antimicrobial activity is linked to
intestinal injury and likely to an impaired wound healing
response.
• Molecules that induce intestinal epithelial restoration are
also important in intestinal inflammation.
Questions to address in the future
• What is the molecular mucus composition and structure
(e.g. role of glycosylation) and its differences in health
versus IBD?
• How is the secretion of phosphatidylcholine and antimicro-
bial effectors within the intestinal mucus layer regulated
and stabilized?
• What are the mechanisms behind the balanced and symbi-
otic relation of bacteria and its host in the intestinal mucus
compartment?
• What is the nature of intestinal ‘barrier breaches’: molec-
ular (tight junction permeability) versus macroscopic?
Which pathways or cell types are responsible for sensing a
breach in the intestinal barrier: NF-κB, MAPKp38, intesti-
nal epithelial cells, dendritic cells?
• How do injury and inflammation intersect to rapidly induce
wound healing mechanisms following an intestinal ‘barrier
breach’ (mucus production, enterocyte proliferation, mi-
gration, apoptosis and cytokine secretion)?
• We need to further refine the technical means to investi-
gate early gastrointestinal wounding/wound healing in
vivo to enable more detailed investigations (e.g. two-
photon-microscopy, lipidomics, proteomics and endoscopic
techniques being the most promising approaches to date).
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4.1. Chronic wound repair and disease complications
In contrast to the intensive investigation of the immunological
mechanisms of the early phases of intestinal inflammation and
repair, the pathophysiology of chronic mucosal wound healing
and the late events of repair remain largely unexplored. This
is unfortunate, because insufficient (abscess, fistula) or exces-
sive wound healing (fibrostenosis) are the main indications for
surgery in patients with CD.75,76 However, this process does
not seem to happen in all patients, as up to one quarter of pa-
tients with CD continue to have a purely inflammatory pheno-
type, even after 25 years of disease.77 In patients with UC,
chronic wound healing can induce fibrotic changes, including
structural changes (haustral loss, colonic shortening), and disor-
dered motility. These findings make it likely that intestinal in-
flammation is an important initiating event, which can either
be followed by normal restitution, or by pathologic fibrosis
and/or fistula formation.76,78 It remains unclear, which signals
and pathways initiate chronic wound healing abnormalities in
late healing, rather than normal restitution and resolution. If
normal restitution and pathologic healing after inflammation
are distinct pathways, these could be separately targeted,
allowing selective therapy for the wound healing abnormalities
seen in IBD.4.2. Extracellular matrix as a driver of inflammation
and wound repair
It is apparent from the study of other organs that undergo fi-
brosis (e.g. lung, liver, and kidney), that once fibrosis is estab-
lished it becomes an independent and self-perpetuating
process, without a necessity for ongoing inflammation to
drive matrix deposition.79 This could be true for fibrotic and
stricturing CD as well. Possible mechanisms include [1] the in-
testinal ECM acting as a binding partner or reservoir for pro-
fibrotic tissue factors,80 [2] the increased stiffness of the tis-
sue acting as a stimulus for mechanosensitive cells to deposit
and crosslink additional extracellular matrix in case of stric-
ture formation, [3] reduced ECM stiffness leading to reduced
matrix deposition in the case of fistulae.81 ECM is not an inac-
tive structure, but directly regulates the inflammatory re-
sponse and the process of healing and fibrosis by focal
adhesions with immune and non-immune cells, such as
myofibroblasts.824.3. Sources of myofibroblasts and mechanisms of
their activation
Activated myofibroblasts, a key effector cell type in intestinal
wound healing, can be derived not only from resident mesen-
chymal cells, but also from other cell populations, including ep-
ithelial and endothelial cells (by a process termed epithelial–/
endothelial–mesenchymal transition), stellate cells, pericytes,
local stem cells, bone-marrow-derived cells, or fibro-
cytes.79,83,84 However, almost nothing is known about the func-
tional relevance, mechanisms and targets for intervention. A
multitude ofmolecules derived fromessentially all cell types in-
volved in IBD can activatemyofibroblasts. In addition, microbialPAMPs or DAMPs, critical for sterile inflammation, could be
involved.85,86
The field of intestinal mesenchymal cells lacks important
technical tools: We need to define specific markers for myo-
fibroblasts, a cell type most critically involved in wound
healing and restitution. Specific subsets of mesenchymal
cells may be identified that are particularly important in
wound repair. Thus far no promoter specific for intestinal
mesenchymal cells/myofibroblasts, useful for the genera-
tion of cell type specific transgenic mice, has been identi-
fied. Markers, such as fibroblast specific protein (FSP)-1
and α-smooth muscle actin (SMA) can be helpful, but are
also expressed in additional cell types in intestinal fibrosis
other than fibroblasts/myofibroblasts.
4.4. Regulation of extracellular matrix turnover
The fine balance between MMPs and TIMPs appears to be dis-
turbed in chronically impaired wound healing in IBD.14 It is
unclear which specific MMPs and TIMPs are involved and how
they are regulated in this process. Our current understanding
of intestinal fibrosis assumes that the amount of accumulated fi-
brotic tissue damage is linked to the likelihood of formation of
fistulae or strictures. Effective pharmacological modulation of
the MMP/TIMP-system could be helpful in the reversal of accu-
mulated tissue fibrosis or healing of already formed fistulae.87
Limited animal models for intestinal fibrosis exist, though
several new models have recently been introduced. Virtually
no animal model exists that helps our understanding of fistu-
la formation. The field is in need of additional factors/mole-
cules able to modulate the wound healing response, which
may include microRNAs. Delivery systems designed to direct
these molecules to the deep layers of the human intestine
need to be developed to allow broad application in clinical
studies. Ultimately, non-invasive means to monitor and
measure intestinal fibrosis and fistula formation in animals
and humans are critical to provide endpoints for developing
and testing specific anti-fibrotic therapies.
4.5. Key messages and questions to address in the
future
Key messages
• Chronic intestinal wound healing abnormalities can lead to
complications, such as formation of strictures or fistulae.
• The extracellular matrix is an active player in intestinal in-
flammation and repair.
• Intestinal myofibroblasts are derived from a multitude of
sources and can be activated by classical pro-inflammatory
signals and growth factors but also by environmental and
bacterial components.
• In chronically impaired wound healing a disturbance of the
MMP/TIMP balance can be observed.
Questions to be addressed in the future
• Which factors determine the switch from a purely inflam-
matory disease course to a complicated disease course?
Do these factors appear early or late in the disease process?
What are the differences between early and late disease?
379Second ECCO Scientific Workshop – Basic mechanisms• Is there a ‘point of no return’ in stricture and fistula formation?
• What are the mechanisms of auto-propagation of intestinal
fibrosis and fistula formation?
• How does the matrix itself actively contribute to the ab-
normalities in wound healing?
• What is the main source of myofibroblasts in intestinal
wound healing?
• What are the specific molecular markers of myofibroblasts?
• What are the main mediators of myofibroblast activation?
What is their functional relevance, what are the mecha-
nisms and targets for intervention?
• What is the role of the environment in activation of intesti-
nal mesenchymal cells (possibly mediated through PAMPs
and DAMPs)?
• What are the sources of MMPs and TIMPs in intestinal in-
flammation? Does an imbalance of this system early in the
disease cause later complications? Can MMPs and TIMPs be
used for the therapy of existing fistulae and strictures?5. Determinants of intestinal healing
The ability to regenerate the intestinal mucosa greatly var-
ies among different IBD patients, as well as, in a given pa-
tient, over time. Such heterogeneity implies the existence
of certain factors influencing the molecular mechanisms re-
sponsible for mucosal healing. On one hand, genetic factors,
including both the genetic background of the patient
and post-transcriptional and epigenetic modifications could
influence mucosal healing. On the other hand, acquired, en-
vironmental or “luminal” factors, such as the bowel micro-
biota, its products, diet components or even drugs might
also play a key role in that process.
5.1. Genetic variants in IBD
5.1.1. Influence of genetic factors on IBD susceptibility
and phenotype
According to our present understanding, both CD and UC de-
velop in genetically susceptible subjects. The fact that ge-
netic factors play a key role in the development of IBD is
beyond any doubt. Many lines of evidence, including a higher
risk in first-degree relatives, studies in monozygotic and di-
zygotic twins, greater prevalence in certain ethnic groups,
identification of specific disease susceptibility genes and
even results from animal models point toward a key role of
genetic factors in IBD. Similarly, the fact that both CD and
UC are polygenic conditions is undisputed. Two recent col-
laborative studies of the International Consortium for the
Study of IBD genetics88,89 have identified 71 single nucleo-
tide polymorphisms (SNPs) independently associated with a
higher risk to develop CD88 and 47 SNPs predisposing to
UC.89 A very interesting concept emerging from these stud-
ies is the fact that some SNPs are common to both entities,
suggesting that these factors facilitate “intestinal inflamma-
tion” in general, whereas other SNPs only increase the risk of
developing either CD or UC, which means that these genetic
factors are “more specific”, influencing only a certain type
of intestinal inflammation.
Compared to our quite comprehensive understanding of
the genetic factors determining CD and UC susceptibility,much less is known about the influence of genetic factors on
disease phenotype, development of IBD-related complications
and response to IBD therapies. The currently strongest
disease-modifying gene seems to be nucleotide-binding oligo-
merization domain containing (NOD)2. Their three main vari-
ants have been associated to increased ileal disease location,
stenosing phenotype and risk of surgery.90,91
5.1.2. Influence of genetic factors on intestinal healing in
IBD patients
Unfortunately, there are no studies specifically aimed at
identifying which genetic factors are independently associ-
ated with a better or worse mucosal healing response in
IBD patients. In spite of this obvious limitation, we can spec-
ulate that the genetic factors influencing, on one hand, the
development of intestinal inflammation and injury and, on
the other hand, the mechanisms of wound healing and repair
might play a relevant role. In the first group a large number
of genes, encoding the expression of molecules critical in in-
flammation and innate immunity, such as the NOD, TLR, and
TNF families might constitute good candidate genes to influ-
ence mucosal healing. In the second gene group, and among
the molecules responsible to regulate the wide spectrum
spanning from physiological wound healing to abnormal
fibrogenesis, several metalloproteinases and their inhibi-
tors, as well as other key regulatory molecules, such as
TGF-β, basic fibroblast growth factor (bFGF), and insulin-
like growth factor (IGF)-1, would be excellent candidates.
To date most efforts in the field of IBD genetics have been
devoted to the identification of DNA-related genetic factors
(single nucleotide polymorphisms). However, the potential
relevance of other types of genetic factors, such as copy
number variants, the degree of gene expression (mRNA),
the existence of inhibitory RNA sequences (microRNAs), as
well as the influence of DNA methylation and other epigenet-
ic changes has been recently recognized and seems likely to
be able to account for part of the observed variation in the
process of mucosal healing in IBD patients. An excellent ex-
ample is the study recently published by Arijs et al.92: Gene
expression was assessed at both blood and tissue levels and
the authors were able to identify a mucosal gene signature
consisting of a combination of 5 expressed genes. This
model showed a high accuracy in predicting response to
infliximab in UC patients, as determined by endoscopic and
histological remission.92
5.2. Impact of butyrate on intestinal healing
As stated above the intestinal luminal compartment, such as
mucus, endogenous anti-microbial factors and the epithelial
barrier are critical in early wound generation and healing in
the intestine. In addition to this an innumerous variety of
compounds is present in the free lumen of our intestines.
A major fraction of these luminal factors, with reported
impact on intestinal healing and the symbiotic host-to-
microorganism relationship are derived directly or indirectly
from bacteria. This occurs via affecting a multitude of im-
mune and non-immune cells of the lamina propria at any
time during development and activation of the human im-
mune system.30 One of the best-characterized bacterial
products known to have beneficial effects on the intestinal
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mentation of starch by members of the anaerobe Clostridium
subphylum species, i.e. clusters IV (Faecalibacterium praus-
nitzii, Butyricicoccus pullicaecorum) and XIVa (Butyrivirio
fibrisolvens).93 Interestingly, both the depletion of these
members and the occurrence of antibodies directed against
their flagellins are linked to IBD.94 As no comprehensive
overview on all bacterial factors involved can possibly be
presented, butyrate will serve as our example for luminal
factors determining intestinal wound healing. The anti-
inflammatory effect of butyrate has been shown in various
in vitro and in vivo systems providing a rationale for asses-
sing its therapeutic potential.95–97 Butyrate can affect
early and late events in intestinal healing.
In vitro stimulation of intestinal biopsies with butyrate in-
creased mucus synthesis.98 In a human colonic goblet cell
line stimulation with butyrate from the apical side of the
cells led to an increase in the expression of MUC2, MUC3 and
MUC5B the genes encoding mucins.99 Very limited information
is available concerning the effects of butyrate on the expres-
sion of antimicrobial peptides. Treatment of colon epithelial
cell lines with butyrate induces upregulation of human cathe-
licidin (LL-37) mRNA expression,100 a lysosomal antibacterial
peptide. This is mediated by recruitment of PU.1 to the cathe-
licidin antimicrobial peptide promoter, the gene encoding LL-
37. Butyrate exhibits a well-established role as a major energy
source for enterocytes, but is also able to stimulate genes that
are important for epithelial integrity, e.g. by affecting histone
acetylation and DNA methylation. Butyrate facilitates tight
junction assembly101 and reduces metabolic stress induced
loss of epithelial integrity — a mechanism that led to protec-
tion from enhanced bacterial translocation.102
Butyrate has been shown to reduce the inflammatory cy-
tokine driven production of MMP-1 and MMP-3 in colonic
myofibroblasts.103 Interestingly, butyrate also reduced the
expression of cytokine-induced IFN-γ-induced protein (IP-
10) by intestinal myofibroblasts, a factor reported to medi-
ate chronic inflammation by recruiting T-cells and mono-
cytes.104 To the contrary, butyrate was shown to enhance
cytokine-induced stromelysin-1 expression thereby contrib-
uting to the inflammatory response.105 More knowledge
about functional consequence of exposure of myofibroblasts
to butyrate is needed.
These diverse actions of butyrate on different phases of in-
testinal wound healing make it likely that additional luminal
factors like bacteria themselves or their released products
have a considerable role in this process. These factors need to
be explored with the prospect as potential future therapeutics.5.3. Molecular action of drugs on intestinal healing
While exploration of the role of genetic, epigenetic or luminal
components to wound healing is critical for the development of
future therapeutic approaches it is also prudent to thoroughly
understand themolecular actions of our current IBD drug reper-
toire. This can help optimize existing treatment protocols by
enhancing their efficacy and reducing their side effects.
Compounds, administered through any route, can signal at
different levels of the intestinal mucosa106: pre-epithelial (in-
testinal mucus, bacteria), epithelial, post-epithelial (mucosal
immune and non-immune compartments, modulation ofcytokines and growth factors) or in a fashion combining all
the above. Although ample data is available on clinical out-
comes of IBD therapy, information regarding mechanisms of
action are scarce.
5.3.1. 5-aminosalicylic acid/sulfasalazine
Treatment with 5-aminosalicylic acid (5-ASA) has been associ-
ated with an abrogation of NFκB activation in situ,107 which
went along with reversal of microscopic alterations in the IBD
mucosa like the mixed inflammatory infiltrate in the lamina
propria, crypt architectural abnormalities, basally located lym-
phoid aggregates, basal plasmacytosis, villiform surface epi-
thelial configuration and Paneth cell metaplasia.108 5-ASA
lowered IL-1β and leukotriene B4 release from cultured biopsy
specimens from the inflamed colonic mucosa of patients with
active inflammatory bowel disease.109 in vitro models show
that sulfasalazine exerted a direct effect on intestinal lamina
propria leukocytes and peripheral blood leukocytes of IBD pa-
tients and healthy subjects, by triggering a potent pro-
apoptotic effect, an action that stood in contrast to 5-ASA.110
Mesalazine is affecting cell migration and proliferation of intes-
tinal epithelial cell lines, two key processes in mucosal healing,
an effect dependent on TGF-β.111 The combination of N-
acetylcysteine plus 5-ASA induced mucosal healing by suppres-
sing cyclooxigenase-2 gene expression and prostaglandin E2
levels in a TNBS rat colitis model.112
5.3.2. Corticosteroids
Corticosteroid-induced healing of colonic inflammation is as-
sociated with a reduction of NFκB in nuclear extracts de-
rived from intestinal mucosal biopsies of IBD patients.113
Dexamethasone lowered the release of IL-1β and leukotri-
ene B4 from IBD derived mucosal biopsies.109 High concen-
trations of prednisolone and budesonide, in contrast to
lower concentrations, had inhibitory effects on proliferation
and restitution of intestinal epithelial cells.114 These results
were partially confirmed by other groups that showed a
steroid-induced inhibition of intestinal epithelial cell migra-
tion and proliferation.115 Dexamethasone suppressed growth
factor induced epithelial restitution by inhibiting prosta-
glandins using two cultured cell wound-resealing models.116
5.3.3. Azathioprine and cyclosporine A
Azathioprine (AZA)-driven mucosal healing was associated
with a decrease of the inflammatory infiltrate in the ileal mu-
cosa from CD patients.117 AZA profoundly inhibits intestinal
epithelial cell growth by causing a G2 cell cycle arrest, induc-
ing apoptosis and dose-dependently inhibiting prolifera-
tion.118 The frequency of intestinal mucosal TNF secreting
cells is reduced in pediatric CD patients upon treatment with
cyclosporin A but not with corticosteroids or enteral nutrition
treatment, although no clear relation existed between histo-
logical healing and the frequency of TNF secreting cells.119
5.3.4. Infliximab
IBD patients receiving the anti-TNF antibody infliximab (IFX)
showed an improvement in their increased intestinal perme-
ability.120 Treatment leads to lower global numbers of CD4+
and CD8+ T lymphocytes and monocytes121 and of mucosal
CD68, a marker for monocytes/macrophages.122 IFX down-
regulatedmucosal expression of forkhead box (Fox)p3, amark-
er for T-regulatory cells, while increasing their circulating
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duced and this effect that was linked to endoscopic and/or his-
tologic improvement.122 IFX lowers the expression of the cell
recruitment molecules intercellular adhesion molecule 1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and lym-
phocyte function-associated antigen 1-(LFA-1). in vitro studies
have shown that infliximab reduces the T-cell secretion of IFN-
γ, likely because its synthesis is dependent on TNF
levels.124,125 IFX attenuated intestinal mucosal MMP-3 and -
12 synthesis but elevated the expression of antimicrobial
peptides.121,126–128 Finally, infliximab treatment was associat-
ed with improvement in morphology and function of the epi-
thelial organelles, mucus secretion and recovery of the
chorionic components at transmission electron microscope
analysis.129
5.3.5. Probiotics
Probiotics can induce regulatory cytokines, including IL-10 and
TGF-β, and suppress TNF, in the mucosa of patients with CD
and pouchitis.130 VSL#3, a probiotic mixture of 8 lactic acid
bacteria probiotic strains or E. coli Nissle 1917, induces IL-10
and downregulates IL-12p40 production by lamina propria den-
dritic cells in patients with UC, changes similar to patients who
were treatedwith corticosteroids.130,131 VSL#3 has been linked
to the enhancement of the increased expression of costimula-
tory molecules like CD80 (B7-1), CD86 (B7-2) and CD40, and of
MHC class II in dendritic cells.131E.coli Nissle 1917 ameliorated
DSS-colitis, an effect likely mediated by toll like receptor
(TLR)-2 and TLR-4.132 The probiotic bacterium bacillus poly-
fermenticus has been shown to increase angiogenic properties
of human intestinal microvascular endothelial cells in a NFκB/
IL-8/chemokine (CXC motif) receptor (CXCR)2-dependent
manner, suggesting that it may be clinically used to facilitate
intestinal wound healing.133
5.3.6. Antibiotics
Even though metronidazole and ciprofloxacin are the most
commonly used antibiotics in IBD many studies were per-
formed on rifaximin, a non-absorbable derivative of rifamycin.
In the TNBS-colitis model rifaximin reduced colitis severity
and decreased the levels of several pro-inflammatory cyto-
kines.134 Ciprofloxacin inhibits the cytokine-induced iNOS
mRNA expression in HT-29 cells and a similar inhibitory effect
was detected in vitro in cultures of normal colonic tissue and
in cultures of colonic tissue from ulcerative colitis patients.135
5.4. Key messages and questions to address in the
future
Key messages
• The link between genetic variants and susceptibility to IBD
has been well established. However information on the in-
fluence of genetic factors on intestinal healing is lacking.
• Luminal factors, directly or indirectly derived from bacte-
ria, have an impact on intestinal healing and could account
for the variability in the wound healing response.
• The mechanisms of action of our current IBD drug reper-
toire are under investigation, but still poorly understood.Questions to address in the future
• What is the influence of different genetic and epigenetic
factors (SNPs, copy number variants, mRNA gene expres-
sion, microRNA expression) — alone or in combination —
on mucosal healing?
• Are local epigenetic changes involved in the focal and seg-
mental nature of fibrosis and fistula formation?
• What are the key components of the luminal compartment
that trigger intestinal inflammation and repair?
• How can the observed alterations in the luminal compart-
ment during intestinal inflammation (e.g. butyrate) be
used to guide us to novel therapeutic approaches?
• We need to develop cell or compartment specific drug de-
livery systems
• How do the currently available IBD therapeutics influence
the late healing response and how do they affect the occur-
rence of complications on a molecular level?Conflict of interest
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